

PRELIMINARY AMENDMENT
National Stage Entry
of PCT/GB2003/004044

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Original) A method for assaying for cAMP in a sample, said method comprising contacting a sample with an unknown cAMP content with a polypeptidic cAMP binding agent and optionally with a labelled cAMP and detecting conjugates of cAMP or labelled cAMP and said binding agent, characterized in that said binding agent comprises functional cAMP B-binding sites only.

Claim 2. (Currently Amended) A method as claimed in claim 1, wherein said binding agent has disabled A-binding sites.

Claim 3. (Currently Amended) A method as claimed in claim 1, ~~or claim 2~~ wherein said binding site is an RI α B-site.

Claim 4. (Currently Amended) A method as claimed in ~~any of the preceding claims~~ claim 1, wherein said labelled cAMP is labelled at the 8-position by iodine-125.

Claim 5. (Currently Amended) A method as claimed in ~~any of the preceding claims~~ claim 1, wherein said labelled cAMP is attached to a substrate surface at the 8-position.

Claim 6. (Currently Amended) A method as claimed in ~~any of the preceding claims~~ claim 1, wherein said cAMP conjugates are detected using surface plasmon resonance.

PRELIMINARY AMENDMENT
National Stage Entry
of PCT/GB2003/004044

Claim 7. (Currently Amended) A method as claimed in ~~any of the preceding claims~~claim 1, wherein said labelled cAMP is labelled with tritium.

Claim 8. (Currently Amended) A method as claimed in ~~any of the preceding claims~~claim 1, wherein said binding site is capable of binding cAMP with a K_D of less than 300% of that of the site in native human cAPK.

Claim 9. (Currently Amended) A method as claimed in ~~any of the preceding claims~~claim 1, wherein said binding site is capable of binding cAMP with a K_D of less than 110% of that of the site in native human cAPK.

Claim 10. (Original) A kit for a cAMP assay, said kit comprising a polypeptidic primary binding agent capable of binding cAMP; optionally, a labelled cAMP; and optionally a secondary binding agent; characterized in that said primary binding agent comprises functional cAPK cAMP B-binding sites only.

Claim 11. (Original) A polypeptidic cAMP binding agent which comprises functional cAPK cAMP B-binding sites only, and compositions and items comprising said binding agent.

Claim 12. (Original) cAMP labelled at the 8-position by iodine-125, and compositions thereof.

Claims 13-14. (Cancelled)

Claim 15. (Original) A method for assaying for a cyclic nucleotide or cyclic nucleotide analog, said method comprising contacting said sample with a polypeptidic binding agent capable of binding said cyclic nucleotide or cyclic nucleotide analog and optionally also with a labelled competitor species capable

PRELIMINARY AMENDMENT
National Stage Entry
of PCT/GB2003/004044

of binding to said binding agent, and detecting conjugates of said binding agent with said cyclic nucleotide or cyclic nucleotide analog or said competitor species, characterized in that said binding agent comprises functional cAPK cAMP B-binding sites only.

Claim 16. (Original) A kit for an assay for a cyclic nucleotide or cyclic nucleotide analog, said kit comprising a polypeptidic primary binding agent capable of binding said cyclic nucleotide or cyclic nucleotide analog; optionally, a labelled competitor species capable of binding to said binding agent; and optionally a secondary binding agent; characterized in that said primary binding agent comprises functional cAPK cAMP B-binding sites only.